Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cogan's syndrome

E W St Clair1, R M McCallum

  • 1Division of Rheumatology, Allergy and Clinical Immunology, Duke University Medical Center, Durham, NC 27710, USA.

Current Opinion in Rheumatology
|January 23, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis.

Scandinavian journal of rheumatology·2014
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same author

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis and rheumatism·2013
Same author

Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.

Clinical and experimental rheumatology·2009
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Cogan's syndrome (CS) is a rare inflammatory condition affecting the eyes and ears. Early corticosteroid treatment is crucial for preserving hearing, with cochlear implants offering partial restoration for severe cases.

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Otolaryngology

Background:

  • Cogan's syndrome (CS) is a rare, chronic inflammatory disorder.
  • It primarily affects young adults, targeting the cornea and vestibuloauditory system.
  • CS presents with interstitial keratitis (IK) and Ménière's-like episodes.

Purpose of the Study:

  • To review the characteristics, pathogenesis, and management of Cogan's syndrome.
  • To emphasize the importance of early diagnosis and treatment for Cogan's syndrome.
  • To discuss treatment options for ocular and auditory manifestations of Cogan's syndrome.

Main Methods:

  • Literature review of Cogan's syndrome.
  • Analysis of clinical presentations and treatment outcomes.
  • Discussion of proposed pathogenetic mechanisms.

Related Experiment Videos

Main Results:

  • CS involves ocular (IK) and audiovestibular (Ménière's-like) symptoms.
  • Associated conditions include aortitis and medium-sized vessel vasculitis.
  • Ocular and audiovestibular symptoms are likely immune-mediated, not vasculitic.

Conclusions:

  • Corticosteroids are the primary treatment for CS, with topical use for IK and systemic use for inner ear dysfunction.
  • Early corticosteroid intervention is critical for preventing irreversible hearing loss.
  • Cochlear implants can provide functional hearing restoration in cases of permanent cochlear damage.